A Phase 1 Study of RMC-6291 in People with KRAS-Mutated Solid Tumors


Full Title

Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mutant Solid Tumors


The purpose of this study is to find the highest dose of the investigational drug RMC-6291 that can be given safely in people with advanced solid tumors that contain a mutation in the KRAS gene (KRAS G12C). KRAS mutations can fuel cancer growth.

RMC-6291 works by blocking proteins that contribute to the growth of cancer cells with a KRAS G12C mutation. By blocking these proteins, RMC-6291 may help slow or stop cancer growth. RMC-6291 is taken orally (by mouth).

Who Can Join

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have an advanced solid tumor that has a KRAS G12C mutation and continues to grow despite prior chemotherapy and immunotherapy.
  • At least 3 weeks must pass between the completion of previous treatment (2 weeks since radiation therapy) and receipt of the study treatment.
  • Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
  • This study is for people age 18 and older.


For more information and to ask about eligibility for this study, please contact the office of Dr. Kathryn Arbour at 646-608-3792.




Phase I (phase 1)



ClinicalTrials.gov ID